Open AccessIncreased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine
Author(s) -
Marc K. Wallack,
S. Muthukumaran,
Kristen Ditaranto,
Palma M. Shaw,
Charles M. Balch,
Marshall M. Urist,
Kirby I. Bland,
Douglas R. Murray,
William A. Robinson,
Lawrence E. Flaherty,
Jon Richards,
Les Rosen,
Alfred A. Bartolucci
Publication year - 1997
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/00000658-199708000-00012
Subject(s) - medicine , vaccinia , melanoma , virology , cancer research , recombinant dna , biochemistry , chemistry , gene
The efficacy of vaccinia melanoma oncolysate (VMO) vaccine to increase overall survival and disease-free survival of patients with surgically resected International Union Against Cancer (UICC) stage II melanoma was studied in a phase III, randomized, multi-institutional trial.